Click here to see Dr. Mahadevan’s curriculum vitae .
Daruka Mahadevan, M.D., Ph. D. has joined The West Clinic as the new Director of the Phase I Clinical Trials Program and Associate Director of Research. He received appointment as Full Professor with the Division of Hematology Oncology at the University of Tennessee Health Science Center (UTHSC).
Dr. Mahadevan is the former Associate Professor of Medicine and Director of the Phase I, New Drug Development Program at the University of Arizona – Arizona Cancer Center. He received his B.Sc. (Hons.) in Physiology and Biochemistry with Chemistry from the University of Reading, England, Ph.D. in protein crystallography from Birkbeck College, University of London and medical degree from King’s College Hospital Medical School, University of London, England, United Kingdom. Dr. Mahadevan completed a post-doctoral Fogarty International fellowship at the National Cancer Institute/NIH and was a senior research scientist at Celltech Therapeutics, London, England. He has written over 70 peer-reviewed full length articles included in Nature, Blood and the Journal of Clinical Oncology; several book chapters; and six U.S. patents on novel agents targeting cancer.
He completed an internal medicine residency at University of Connecticut and fellowship training in Hematology/Oncology at the AZCC. Dr. Mahadevan is certified by the American Board of Internal Medicine and Medical Oncology.
“I am excited to be joining The West Clinic to help build a world-class Phase I program of translational research with the University of Tennessee in collaboration with ACORN Research,” stated Dr. Mahadevan. “. This will be a great service to patients in our care. In addition, this will be a great research opportunity to learn from this experience and build new molecules into frontline cancer therapies.”
Noted internationally for his accomplishments in building the Phase I Program at the University of Arizona, Dr. Mahadevan’s major area of clinical research interest is in the treatment and management of patients with Pancreatic cancer, Gastrointestinal Stromal Tumors (GIST), Myelodysplastic Syndromes (MDS) and non-Hodgkin’s lymphoma (NHL) including Chronic Lymphocytic Leukemia (CLL). As Director of the Phase I Program, he will conduct first-in-human clinical trials with novel drugs for patients with all solid tumor types as well as patients with MDS, CLL and NHL.
“Dr. Mahadevan is the first translational scientist to join The West Clinic. He will play a pivotal role as a foundational scientist to bring the development of our cancer center with Methodist Le Bonheur Healthcare and University of Tennessee Health Science Center to fruition,” according to Lee S. Schwartzberg, MD, Medical Director. “The West Clinic has been building its clinical research program for many years, and we are focused on expanding our Phase 1 capabilities. We are extremely excited to recruit Dr. Mahadevan as Director of our Phase I Program. He brings a wealth of experience and academic rigor as an experienced scientist to our efforts. He organized the Phase I Program at the University of Arizona and will further develop our Phase I Program and research capabilities to new heights, allowing us to offer the most comprehensive clinical trials program in the region. This will enhance our capabilities to compete with any center in the United States.”
The West Clinic’s clinical research program is internationally renowned. Over the past two decades, The West Clinic has consistently been one of the first centers in the nation to gain experience and hasten the development of new drugs for breast cancer, colon cancer, lung cancer, prostate cancer, lymphoma, and many other diseases. Our researchers are currently investigating new drug therapies through participation in over 40 clinical trials.